Denizot Yves, Guglielmi Laurence, Donnard Magali, Trimoreau Franck
UMR CNRS 6101, Faculté de Médecine, 2 rue Dr Marcland, 87025, Limoges, France.
Leuk Lymphoma. 2003 May;44(5):775-82. doi: 10.1080/1042819031000067549.
Platelet-activating factor (PAF), a phospholipid mediator with a wide range of actions on mature leukocytes, acts directly during early human haematopoiesis by affecting the growth of haematopoietic progenitors and indirectly, by modulating cytokine synthesis by bone marrow stromal cells. At this time, its role during leukaemic diseases remains speculative. The lack of membrane PAF receptor (PAF-R) on leukaemic blasts suggest that this receptor represents a marker of mature cells and its membrane induction a consequence of cell maturation. While the couple PAF/PAF-R has been largely studied using B cell lines, few results are available using B cells of patients with haematopoietic malignancies casting some doubts concerning the potential role (if any) of this molecule during leukaemic diseases.
血小板活化因子（PAF）是一种对成熟白细胞有广泛作用的磷脂介质，在人类早期造血过程中，它通过影响造血祖细胞的生长直接发挥作用，并通过调节骨髓基质细胞的细胞因子合成间接发挥作用。目前，它在白血病中的作用仍具有推测性。白血病原始细胞上缺乏膜PAF受体（PAF-R），这表明该受体是成熟细胞的标志物，其膜诱导是细胞成熟的结果。虽然PAF/PAF-R这对组合已在很大程度上通过B细胞系进行了研究，但利用造血系统恶性肿瘤患者的B细胞获得的结果很少，这让人对该分子在白血病中的潜在作用（如果有）产生了一些怀疑。
